XBiotech (XBIT) Share-based Compensation (2014 - 2026)
XBiotech (XBIT) posted quarterly Share-based Compensation of $162000.0 for Q4 2025, down 74.2% year-over-year from $628000.0 in Q4 2024, and down 99.89% quarter-over-quarter from $150.0 million in Q3 2025.
XBiotech (XBIT) Share-based Compensation (2014 - 2026) Analysis & Trends
XBiotech's Share-based Compensation history runs 12 years deep, the most recent figure standing at $162000.0 for Q4 2025.
- In Q4 2025, Share-based Compensation fell 74.2% year-over-year to $162000.0; the TTM figure through Dec 2025 stood at $4.5 million (up 214.23% YoY), while the FY2025 annual figure was $3.6 million, up 106.62% from the prior year.
- Share-based Compensation for Q4 2025 stood at $162000.0, down from $150.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $150.0 million in Q3 2025, with the low at -$2.6 million in Q4 2023.
- The 5-year median for Share-based Compensation is $945500.0 (2021), against an average of $13.3 million.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation sank 347.5% in 2023, then soared 40995.89% in 2025.
- XBiotech's Share-based Compensation stood at $4.9 million in 2021, then tumbled by 78.76% to $1.0 million in 2022, then plunged by 347.5% to -$2.6 million in 2023, then soared by 124.45% to $628000.0 in 2024, then plunged by 74.2% to $162000.0 in 2025.
- Business Quant data shows XBIT's Share-based Compensation at $162000.0 in Q4 2025, $150.0 million in Q3 2025, and $98.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | XBiotech | 68.90 Mn | 68.90 Mn | - | 172,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 172,000.00 |
| Jun 30, 2026 | 172,000.00 |
| Dec 31, 2025 | 162,000.00 |
| Dec 31, 2025 | 162,000.00 |
| Sep 30, 2025 | 150.00 Mn |
| Sep 30, 2025 | 150.00 Mn |
| Jun 30, 2025 | 98.00 Mn |
| Jun 30, 2025 | 98.00 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Mar 31, 2025 | 3.33 Mn |
| Dec 31, 2024 | 628,000.00 |
| Dec 31, 2024 | 628,000.00 |
| Sep 30, 2024 | 365,000.00 |
| Sep 30, 2024 | 365,000.00 |
| Jun 30, 2024 | 379,000.00 |
| Jun 30, 2024 | 379,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Mar 31, 2024 | 55,000.00 |
| Dec 31, 2023 | -2.57 Mn |
| Dec 31, 2023 | -2.57 Mn |